Ashkon Software

   







 


CEMP - Cempra, Inc.

Cempra, Inc. logo CEMP or Cempra, Inc. is a pharmaceutical company that develops and commercializes antibiotics for acute bacterial infectious diseases. The company was founded in 2006 and is headquartered in Chapel Hill, North Carolina.

CEMP has a number of products in its pipeline, including solithromycin, a novel macrolide antibiotic for the treatment of community-acquired bacterial pneumonia (CABP), and fusidic acid, a topical antibiotic for the treatment of impetigo.

In addition to its product pipeline, CEMP has partnerships with various organizations to further its research and development efforts. The company has a collaboration agreement with Optimer Pharmaceuticals for the development of certain antibiotics, and it has also partnered with the Biomedical Advanced Research and Development Authority (BARDA) to develop antibiotics for biodefense and emerging infectious diseases.

Despite the potential of its pipeline products, CEMP has faced some setbacks in recent years. In December 2016, the company announced that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) for solithromycin. The FDA requested additional safety and efficacy data for the drug, delaying its potential approval.

CEMP's stock price has fluctuated significantly in response to these developments, and investors should be aware of the risks associated with investing in pharmaceutical companies, particularly those in the early stages of drug development.

Overall, CEMP's focus on developing novel antibiotics for infectious diseases is an important area of research, and if the company can successfully navigate the regulatory hurdles, its products could have a significant impact on public health. However, investors should carefully consider the risks associated with investing in a company in the pharmaceutical industry, particularly given the uncertainty surrounding FDA approval

 



 

 

 
Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer